Trials / Recruiting
RecruitingNCT05956821
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 1 Year – 21 Years
- Healthy volunteers
- Accepted
Summary
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
Conditions
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Fibrillary Astrocytomas
- Oligodendroglioma
- Diffuse Intrinsic Brainstem Glioma
- Diffuse Intrinsic Pontine Glioma
- DIPG Brain Tumor
- H3 K27M
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SIACI of cetuximab and bevacizumab | Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2) |
Timeline
- Start date
- 2025-06-19
- Primary completion
- 2029-10-01
- Completion
- 2029-12-01
- First posted
- 2023-07-21
- Last updated
- 2025-12-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05956821. Inclusion in this directory is not an endorsement.